Test is first-to-market, non-invasive IVD assay for reliable detection of both Helicobacter pylori and clarithromycin resistance from stool sample
Espoo, Finland – June 3, 2015 – Mobidiag Ltd, a Finnish molecular diagnostics company specialized in the development of innovative diagnostics solutions for infectious diseases, today announced the CE-IVD marking of Amplidiag™ H. pylori+ClariR. The qualitative qPCR-based test expands the gastrointestinal Amplidiag test menu and is immediately available throughout Europe. The first-to-market, non-invasive molecular diagnostic test reliably detects the gastric pathogen H. pylori as well as one of its key resistances to clarithromycin. The test is performed directly from stool DNA extract in a rapid manner.